Genetic Engineering & Biotechnology News

SEP15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 74 of 77

Wednesday, September 27, 2017 11:00 am ET 8: 00 am PT DURATION 60 minutes COST Complimentary Speakers Prioritizing the Indications in Your Drug Discovery Portfolio The number of indications available to drug hunters is growing dramatically, yet the return on investment is declining—why? Traditional approaches for indication prioritization cannot be scaled to screen the increasingly segmented disease landscape systematically. Novel methods are therefore required. For those approaches to be effective, an indication prioritization approach must systematically find the most meaningful candidates across thousands of indications, leveraging chemical, biological, clinical, regulatory, and commercial data points. In this GEN webinar, we will find out how pharma and biotech companies looking to evaluate compounds and targets across their portfolio can now leverage extensive biological pathway data and advanced bioinformatics, combined with development feasibility and commercial metrics. The result is the ability to explore and prioritize thousands of indications more systematically and cost-effectively. A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists. Who Should Attend • Investigators evaluating compounds/ targets across indication s • Translational research scientists • Drug discovery scientists • Pharmacologists • Medicinal chemists Free Registration! Webinars You Will Learn • How a novel approach for systematic and cost-effective prioritization of indications can help you to identify the most meaningful indications for your portfolio • Prioritization methodology that will aid in streamlining your drug discovery workflows • How the development of a unique and novel approach was essential to prioritize indications at a scale systematically Produced with support from Marina Bessarabova, Ph.D. Senior Director, Discovery and Translational Practice Clarivate Analytics Tsz Mon Tsang, M.Sc., Ph.D. Senior Consultant, Portfolio & Licensing Clarivate Analytics

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - SEP15 2017